Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership Technicals

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E
FONR	FONAR CORP	NASDAQ	Diagnostics & Research	$110.86M	$16.52	-1.61%	$25.75M	8.74x	0.28
ICLR	ICON PLC	NASDAQ	Diagnostics & Research	$24.09B	$292.02	-0.68%	$1.55B	39.14x	0.84
IDXX	IDEXX LABORATORIES INC	NASDAQ	Diagnostics & Research	$39.74B	$478.24	-2.31%	$1.22B	47.02x	1.20
STRR	STAR EQUITY HOLDINGS INC	NASDAQ	Diagnostics & Research	$13.95M	$0.88	0.57%	$26.87M	0.55x	0.16
RVTY	REVVITY INC	NYSE	Diagnostics & Research	$12.42B	$100.55	0.27%	$1.25B	18.08x	0.72
A	AGILENT TECHNOLOGIES INC	NYSE	Diagnostics & Research	$39.43B	$134.55	-1.64%	$1.69B	31.88x	0.77
NEOG	NEOGEN CORP	NASDAQ	Diagnostics & Research	$2.63B	$12.14	-0.16%	$188.76M	607.00x	0.46
MEDP	MEDPACE HOLDINGS INC	NASDAQ	Diagnostics & Research	$11.76B	$382.44	-0.68%	$382.14M	41.57x	1.96
QGEN	QIAGEN NV	NYSE	Diagnostics & Research	$8.95B	$39.23	-0.23%	$688.56M	26.15x	0.61
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	NYSE	Diagnostics & Research	$11.82B	$230.09	-0.97%	$1.03B	24.82x	1.26
TMO	THERMO FISHER SCIENTIFIC INC	NYSE	Diagnostics & Research	$208.67B	$547.25	-1.32%	$11.06B	35.26x	1.11
SHC	SOTERA HEALTH CO	NASDAQ	Diagnostics & Research	$3.04B	$10.75	-1.29%	$406.83M	59.72x	6.06
ENZ	ENZO BIOCHEM INC	NYSE	Diagnostics & Research	$58.91M	$1.15	0.00%	$33.74M	1.72x	0.40
LH	LABORATORY CORP OF AMERICA HOLDINGS	NYSE	Diagnostics & Research	$16.82B	$199.97	-0.97%	$1.55B	41.66x	1.12
DHR	DANAHER CORP	NYSE	Diagnostics & Research	$177.08B	$239.39	-0.40%	$8.04B	37.17x	0.58
CSTL	CASTLE BIOSCIENCES INC	NASDAQ	Diagnostics & Research	$517.16M	$18.84	-0.53%	-$45.02M	-8.80x	0.16
TWST	TWIST BIOSCIENCE CORP	NASDAQ	Diagnostics & Research	$1.65B	$28.57	-0.14%	-$169.85M	-7.91x	0.24
DGX	QUEST DIAGNOSTICS INC	NYSE	Diagnostics & Research	$14.06B	$126.98	-0.35%	$1.69B	16.73x	1.22
MTD	METTLER TOLEDO INTERNATIONAL INC	NYSE	Diagnostics & Research	$25.73B	$1,198.03	-2.46%	$1.17B	33.19x	-23.38
WAT	WATERS CORP	NYSE	Diagnostics & Research	$18.01B	$304.18	-3.04%	$1.00B	27.98x	3.02
XGN	EXAGEN INC	NASDAQ	Diagnostics & Research	$24.13M	$1.40	-2.44%	-$18.21M	-1.04x	1.51
SERA	SERA PROGNOSTICS INC	NASDAQ	Diagnostics & Research	$313.88M	$9.68	-1.22%	-$34.76M	-8.34x	0.36
IQV	IQVIA HOLDINGS INC	NYSE	Diagnostics & Research	$41.25B	$227.25	-0.82%	$3.26B	30.75x	3.37
EXAS	EXACT SCIENCES CORP	NASDAQ	Diagnostics & Research	$11.48B	$63.22	-1.00%	$52.20M	-55.95x	1.06
PSNL	PERSONALIS INC	NASDAQ	Diagnostics & Research	$60.60M	$1.20	-3.23%	-$94.95M	-0.53x	0.74
NTRA	NATERA INC	NASDAQ	Diagnostics & Research	$10.91B	$90.33	0.01%	-$383.28M	-23.90x	0.88
PRPO	PRECIPIO INC	NASDAQ	Diagnostics & Research	$9.59M	$6.71	-0.46%	-$4.32M	-1.49x	0.25
OLK	OLINK HOLDING AB (PUBL)	NASDAQ	Diagnostics & Research	$2.77B	$22.29	-1.63%	-$20.05M	-89.16x	0.20
DRIO	DARIOHEALTH CORP	NASDAQ	Diagnostics & Research	$35.63M	$1.21	3.42%	-$54.38M	-0.63x	0.66
ACRS	ACLARIS THERAPEUTICS INC	NASDAQ	Diagnostics & Research	$87.24M	$1.23	0.82%	-$87.99M	-0.97x	0.26
FLGT	FULGENT GENETICS INC	NASDAQ	Diagnostics & Research	$598.38M	$20.09	-3.04%	-$134.12M	-3.57x	0.09
STIM	NEURONETICS INC	NASDAQ	Diagnostics & Research	$117.83M	$3.96	-1.98%	-$22.76M	-3.77x	2.39
DMTK	DERMTECH INC	NASDAQ	Diagnostics & Research	$20.50M	$0.59	-3.58%	-$95.04M	-0.19x	1.13
GH	GUARDANT HEALTH INC	NASDAQ	Diagnostics & Research	$1.99B	$16.39	1.42%	-$433.31M	-3.83x	10.26
NEO	NEOGENOMICS INC	NASDAQ	Diagnostics & Research	$1.75B	$13.68	-1.23%	-$8.37M	-19.54x	0.79
OCX	ONCOCYTE CORP	NASDAQ	Diagnostics & Research	$21.43M	$2.59	-5.82%	-$26.05M	-0.69x	2.41
BNR	BURNING ROCK BIOTECH LTD	NASDAQ	Diagnostics & Research	$81.92M	$0.80	5.26%	N/A	-0.90x	0.35
BGLC	BIONEXUS GENE LAB CORP	NASDAQ	Diagnostics & Research	$11.18M	$0.63	0.48%	-$2.49M	-3.46x	0.18
RDNT	RADNET INC	NASDAQ	Diagnostics & Research	$3.27B	$47.80	-0.19%	$265.49M	956.00x	2.98
APDN	APPLIED DNA SCIENCES INC	NASDAQ	Diagnostics & Research	$5.65M	$0.33	-3.20%	-$5.89M	-0.61x	1.37
LAB	STANDARD BIOTOOLS INC	NASDAQ	Diagnostics & Research	$757.21M	$2.61	-3.69%	-$65.66M	-2.78x	-1.08
PRE	PRENETICS GLOBAL LTD	NASDAQ	Diagnostics & Research	$38.16M	$3.15	-1.87%	N/A	-0.56x	0.21
XWEL	XWELL INC	NASDAQ	Diagnostics & Research	$5.81M	$1.39	1.46%	-$24.16M	-0.21x	1.39
CDNA	CAREDX INC	NASDAQ	Diagnostics & Research	$428.73M	$8.28	5.48%	-$182.19M	-2.34x	0.79
MDXH	MDXHEALTH SA	NASDAQ	Diagnostics & Research	$6.22M	$2.30	-2.95%	-$20.47M	-0.14x	16.92
BDSX	BIODESIX INC	NASDAQ	Diagnostics & Research	$117.30M	$1.21	-3.20%	-$37.10M	-1.89x	20.64
NDRA	ENDRA LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$2.55M	$0.23	-16.00%	-$9.78M	-0.15x	0.19
CHEK	CHECK-CAP LTD	NASDAQ	Diagnostics & Research	$12.75M	$2.18	-1.80%	-$19.08M	-0.72x	0.06
ME	23ANDME HOLDING CO	NASDAQ	Diagnostics & Research	$171.92M	$0.36	-8.72%	-$490.64M	-0.32x	0.61
ULS	UL SOLUTIONS INC	NYSE	Diagnostics & Research	N/A	$33.99	-2.41%	$519.00M	26.15x	3.15
PRPH	PROPHASE LABS INC	NASDAQ	Diagnostics & Research	$113.14M	$6.27	-14.69%	-$14.83M	-6.40x	0.86
AWH	ASPIRA WOMEN's HEALTH INC	NASDAQ	Diagnostics & Research	$43.08M	$3.49	1.16%	-$16.50M	-1.93x	-3.65
OPK	OPKO HEALTH INC	NASDAQ	Diagnostics & Research	$871.24M	$1.25	3.31%	-$65.62M	-5.00x	0.45
NOTV	INOTIV INC	NASDAQ	Diagnostics & Research	$139.79M	$5.42	-3.56%	$59.57M	-4.17x	2.29
VNRX	VOLITIONRX LTD	NYSEMKT	Diagnostics & Research	$48.75M	$0.59	-4.19%	-$33.68M	-1.19x	-4.70
ISPC	ISPECIMEN INC	NASDAQ	Diagnostics & Research	$1.94M	$0.21	0.47%	-$9.02M	-0.17x	0.62
GENE	GENETIC TECHNOLOGIES LTD	NASDAQ	Diagnostics & Research	$729.44k	$3.16	-0.32%	N/A	-1.06x	0.76
MYGN	MYRIAD GENETICS INC	NASDAQ	Diagnostics & Research	$1.68B	$18.64	-1.48%	-$186.10M	-5.86x	0.46
BIAF	BIOAFFINITY TECHNOLOGIES INC	NASDAQ	Diagnostics & Research	$33.51M	$2.91	2.83%	-$7.63M	-3.20x	0.69
PMD	PSYCHEMEDICS CORP	NASDAQ	Diagnostics & Research	$14.59M	$2.54	-0.78%	-$768.00k	-3.53x	0.85
ILMN	ILLUMINA INC	NASDAQ	Diagnostics & Research	$18.80B	$118.29	0.51%	-$608.00M	-16.12x	0.76
MYNZ	MAINZ BIOMED NV	NASDAQ	Diagnostics & Research	$19.71M	$0.93	-2.31%	-$24.62M	-0.57x	3.74
TRIB	TRINITY BIOTECH PLC	NASDAQ	Diagnostics & Research	$14.10M	$1.84	-0.81%	N/A	N/A	-3.48
MMA	ALTA GLOBAL GROUP LTD	NYSEMKT	Diagnostics & Research	N/A	$3.13	3.99%	-$16.12M	-0.60x	-0.55
CNTG	CENTOGENE NV	NASDAQ	Diagnostics & Research	$13.25M	$0.48	0.00%	-$44.39M	-0.30x	-5.72
TTOO	T2 BIOSYSTEMS INC	NASDAQ	Diagnostics & Research	$16.21M	$2.94	-2.97%	-$42.53M	-0.15x	-2.24

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 1.98% over the past year, overperforming other diagnostic & research stocks by 11 percentage points.

2. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -0.68% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 22.11% from Idexx Laboratories's current stock price of $478.24.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 36.48% over the past year, overperforming other diagnostic & research stocks by 46 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 18.63% from Icon's current stock price of $292.02.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.26%, which is 2 percentage points higher than the diagnostic & research industry average of 1.42%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.27%, which is 1 percentage points higher than the diagnostic & research industry average of 1.42%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.44%, which is the same as the diagnostic & research industry average of 1.42%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.48% in the last day, and down -6.34% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 8.64% in the past year. It has overperformed other stocks in the diagnostic & research industry by 18 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -54.9% in the past year. It has underperformed other stocks in the diagnostic & research industry by -45 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 1.98% in the past year. It has overperformed other stocks in the diagnostic & research industry by 11 percentage points.

Are diagnostic & research stocks a good buy now?

46.81% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 12.64% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.63x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.